Vapotherm - VAPO Stock Forecast, Price & News

Vapotherm, Inc., a medical technology company, focuses on the development and commercialization of proprietary high velocity therapy products used to treat patients of various ages suffering from respiratory distress in the United States and internationally. The company offers precision flow systems, such as Precision Flow Hi-VNI, Precision Flow Plus, Precision Flow Classic, and Precision Flow Heliox that deliver heated, humidified, and oxygenated air at a high velocity to patients through a small-bore nasal interface. It also provides companion products, including Vapotherm Transfer Unit, which allows patients to be transferred between care areas within the hospital or ambulate while on therapy; Q50 compressor, which provides compressed air necessary to run the precision flow systems; aerosol aeroneb adaptor to facilitate delivery of ultrasonic aerosolized medication; aerosol disposable patient circuit that is designed to streamline the provision of continuous and intermittent delivery of aerosol medication; and tracheostomy adaptors. In addition, Vapotherm, Inc. offers ProSoft cannula to provide gentle contact with the skin; and disposable products comprising single-use disposables and nasal interfaces, as well as Oxygen Assist Modules, which helps clinicians maintain oxygen levels within a target range. The company sells its products to hospitals. Vapotherm, Inc. was founded in 1993 and is headquartered in Exeter, New Hampshire.

Vapotherm Stock Performance

Shares of VAPO Stock remained flat at $1.80 during mid-day trading on Monday. 2,765 shares of the stock were exchanged, compared to its average volume of 299,908. Vapotherm has a 12-month low of $1.62 and a 12-month high of $31.87. The firm's 50 day moving average price is $2.42 and its 200 day moving average price is $7.36. The company has a quick ratio of 3.25, a current ratio of 5.29 and a debt-to-equity ratio of 7.04. The stock has a market cap of $48.05 million, a price-to-earnings ratio of -0.49 and a beta of -0.22.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on VAPO. William Blair cut Vapotherm from an "outperform" rating to a "market perform" rating in a research note on Thursday, August 4th. Piper Sandler reduced their price objective on Vapotherm from $2.50 to $2.00 and set an "underweight" rating on the stock in a research note on Thursday, August 4th. Canaccord Genuity Group cut Vapotherm from a "buy" rating to a "hold" rating and reduced their price objective for the company from $12.00 to $5.00 in a research note on Friday, May 6th. Canaccord Genuity Group cut Vapotherm from a "buy" rating to a "hold" rating and cut their target price for the stock from $12.00 to $5.00 in a research note on Friday, May 6th. Finally, BTIG Research lowered shares of Vapotherm from a "buy" rating to a "neutral" rating in a report on Thursday, August 4th. One equities research analyst has rated the stock with a sell rating and four have assigned a hold rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Hold" and an average target price of $4.75.

Insider Activity at Vapotherm

In other news, Director Anthony L. Arnerich bought 10,000 shares of the stock in a transaction that occurred on Wednesday, June 1st. The shares were bought at an average price of $3.06 per share, for a total transaction of $30,600.00. Following the purchase, the director now owns 53,374 shares in the company, valued at $163,324.44. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, Director Anthony L. Arnerich purchased 20,000 shares of the firm's stock in a transaction on Tuesday, August 9th. The shares were acquired at an average price of $1.65 per share, for a total transaction of $33,000.00. Following the purchase, the director now directly owns 73,374 shares in the company, valued at $121,067.10. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Anthony L. Arnerich purchased 10,000 shares of the firm's stock in a transaction on Wednesday, June 1st. The stock was bought at an average price of $3.06 per share, for a total transaction of $30,600.00. Following the purchase, the director now owns 53,374 shares in the company, valued at $163,324.44. The disclosure for this purchase can be found here. In the last quarter, insiders have bought 40,000 shares of company stock worth $92,200. 10.60% of the stock is owned by corporate insiders.